Assessing the Financial Value of Patient Engagement A Quantitative Approach from CTTI’s Patient Groups and Clinical Trials Project

• Published in: Therapeutic innovation & regulatory science Vol. 52; no. 2; pp. 220 - 229
• Main Authors: Levitan, Bennett, Getz, Kenneth, Eisenstein, Eric L., Goldberg, Michelle, Harker, Matthew, Hesterlee, Sharon, Patrick-Lake, Bray, Roberts, Jamie N., DiMasi, Joseph
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.03.2018; Springer International Publishing
• Subjects: Clinical Trials as Topic - economics; Drug Safety and Pharmacovigilance; Humans; Models, Economic; Patient Engagement; Patient Engagement: Original Research; Patient Participation - economics; Pharmacotherapy; Pharmacy; Public-Private Sector Partnerships; risk-adjusted financial model; patient engagement; expected net present value; therapeutic development
• ISSN: 2168-4790; 2168-4804; 2168-4804
• DOI: 10.1177/2168479017716715

Background: While patient groups, regulators, and sponsors are increasingly considering engaging with patients in the design and conduct of clinical development programs, sponsors are often reluctant to go beyond pilot programs because of uncertainty in the return on investment. We developed an approach to estimate the financial value of patient engagement. Methods: Expected net present value (ENPV) is a common technique that integrates the key business drivers of cost, time, revenue, and risk into a summary metric for project strategy and portfolio decisions. We assessed the impact of patient engagement on ENPV for a typical oncology development program entering phase 2 or phase 3. Results: For a pre–phase 2 project, the cumulative impact of a patient engagement activity that avoids one protocol amendment and improves enrollment, adherence, and retention is an increase in net present value (NPV) of $62MM ($65MM for pre–phase 3) and an increase in ENPV of $35MM ($75MM for pre–phase 3). Compared with an investment of $100,000 in patient engagement, the NPV and ENPV increases can exceed 500-fold the investment. This ENPV increase is the equivalent of accelerating a pre–phase 2 product launch by 2½ years (1½ years for pre–phase 3). Conclusions: Risk-adjusted financial models can assess the impact of patient engagement. A combination of empirical data and subjective parameter estimates shows that engagement activities with the potential to avoid protocol amendments and/or improve enrollment, adherence, and retention may add considerable financial value. This approach can help sponsors assess patient engagement investment decisions.